secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001193125-24-213225
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics appoints Dr. Jakob Dupont to Board; two directors resign
-----------------------------------------------------------------------------

- James Healy, M.D., Ph.D., resigned from Board effective Sept 3, 2024; no disagreement with company.
- Frank D. Lee also resigned from Board effective Sept 3, 2024; no disagreement with company.
- Board appointed Jakob Dupont, M.D., Ph.D., as Class II director effective Sept 3, 2024.
- Dr. Dupont is Executive Venture Partner at Sofinnova Investments; former Global Head of R&D at Atara Bio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/d886159d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-213225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer